Abstract: The present invention relates to novel integrin antagonists of Formula (I) and their use as a medicament, in particular for inhibiting neovascularization.

Abstract: The present invention relates to novel integrin antagonists of Formula I and their use as a medicament, in particular for inhibiting neovascularization.

Abstract: The present invention relates to novel integrin antagonists of Formula I and their use as a medicament, in particular for inhibiting neovascularization.

Abstract: The invention concerns a hydraulic steering (1) with a steering motor (8), a steering unit (2) with feedback behavior, a steering member activating the steering unit (2) and a shock valve arrangement (50) between the steering motor (8) and the steering unit (2). It is endeavored to enable changes of the feedback behavior in a simple manner. For this purpose it is ensured that a switchable feedback suppression device (9) is located at the side of the shock valve arrangement (50) facing away from the steering motor (8).

Abstract: The invention concerns a hydraulic steering (1) with a steering valve (7) located between a supply connection arrangement (P, T) and a steering motor (2). It is endeavored to improve the safety of such a steering. For this purpose, the steering valve (7) has a hydraulic drive (9, 10) with a pilot valve arrangement (11) supplied by a pressure control valve (5), a stop valve (16) being located between the pressure control valve (5) and the pilot valve arrangement (11).

Abstract: Methods and compositions are disclosed for the reduction of immune responses to an exogenous allergen. The reduction is obtained by pre-treatment or pre-conditioning, without injection, of a subject with the allergen so as to reduce immune responses in the subject upon additional exposure to the allergen. The invention is advantageously used in a variety of contexts, including seasonal allergies wherein pre-treatment or pre-conditioning is performed before the onset of the seasonal allergy.

Abstract: The invention concerns a hydraulic steering (1) with a steering valve (7) located between a supply connection arrangement (P, T) and a steering motor (2). It is endeavoured to improve the safety of such a steering. For this purpose, the steering valve (7) has a hydraulic drive (9, 10) with a pilot valve arrangement (11) supplied by a pressure control valve (5), a stop valve (16) being located between the pressure control valve (5) and the pilot valve arrangement (11).

Abstract: The invention concerns a hydraulic steering (1) with a steering motor (8), a steering unit (2) with feedback behaviour, a steering member activating the steering unit (2) and a shock valve arrangement (50) between the steering motor (8) and the steering unit (2). It is endeavoured to enable changes of the feedback behaviour in a simple manner. For this purpose it is ensured that a switchable feedback suppression device (9) is located at the side of the shock valve arrangement (50) facing away from the steering motor (8).

Abstract: Methods and compositions are disclosed for the reduction of immune responses to an exogenous allergen. The reduction is obtained by pre-treatment or pre-conditioning, without injection, of a subject with the allergen so as to reduce immune responses in the subject upon additional exposure to the allergen. The invention is advantageously used in a variety of contexts, including seasonal allergies wherein pre-treatment or pre-conditioning is performed before the onset of the seasonal allergy.

Abstract: The invention concerns a fully hydraulic steering with a steering member, a steering unit that can be activated by the steering member, said steering unit comprising a supply connection arrangement (P, T) with a pressure connection (P) and a tank connection (T), and a working connection arrangement (L, R) with two working connections (L, R), and a steering motor, which is connected with the working connection arrangement (L, R). It is endeavored to increase the possibilities of steering. For this purpose, it is ensured that an auxiliary force operated steering valve is arranged in parallel to the steering unit between the supply connection arrangement (P, T) and the working connection arrangement (L, R).

Abstract: The invention concerns a fully hydraulic steering with a steering member, a steering unit that can be activated by the steering member, said steering unit comprising a supply connection arrangement (P, T) with a pressure connection (P) and a tank connection (T), and a working connection arrangement (L, R) with two working connections (L, R), and a steering motor, which is connected with the working connection arrangement (L, R). It is endeavoured to increase the possibilities of steering. For this purpose, it is ensured that an auxiliary force operated steering valve is arranged in parallel to the steering unit between the supply connection arrangement (P, T) and the working connection arrangement (L, R).

Abstract: The present patent application relates to compounds having formula (I) or a pharmaceutically acceptable salt thereof wherein one of R1, R2 and R3 is a non-cyclic acidic group having a pKa value below 8 or a group which is in vivo convertible to such a group; R4, R5 and the other two of the substituents R1, R2 and R3 are each independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro, amnino, and aryl, aralkyl, arylamino, aryloxy, aryl—CO—, or heteroaryl, wherein the aryl and heteroaryl groups may be substituted one or more times with substituents selected from alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, hydroxy, alkoxy, halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro and amino; or R3 and R4 or R4 and R5 together form a fused 4- to 7-membered carbocyclic ring which may be unsaturated, or partially or fully saturated, while the other substituents R1, R2, R3, R4 and R5 are as

Abstract: A compound having the formula (I) or a pharmaceutically acceptable salt thereof where the variables are defined in the specification are useful in the treatment of sickle-cell anemia.

Abstract: Peptides of the general formula (I): I-A-B-C-D-E-F-G-H-II are disclosed as being active against Herpes virus infections in animals and human beings, wherein A is Ala, Gly, Val or absent; B is Ala, Gly, Val, Ser or absent; C is Ser, Thr or absent; D is Ser, Thr, Ans, Glu, Arg, Ile, Leu or absent; E is Ser, Thr, Asp or absent; F is Thr, Ser, Asn, Gln, Lys, Trp or absent; G is Tyr or absent; H is Thr, Gly, Met, Met(O), Cys, Thr or Gly; I is Cys or absent, and II is Cys, an amide group, substituted amide group, an ester group or absent, wherein the peptides comprise at least 4 amino acids and physiologically acceptable salts thereof.

Abstract: A compound having the formula ##STR1## or a pharmaceutically acceptable salt thereof, whereinX, Z, Y, A, D, E, F, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.11, R.sup.12 have the meanings set forth in the specification, pharmaceutical compositions comprising the same, and a method of treating therewith.The compounds are useful as potassium channel openers.